Colorectal Cancer News

New Study for Metastatic Colorectal Cancer Patients with Wild-Type KRAS Marker

This trial will evaluate a new c-met inhibitor called ARQ-197. The c-met pathway is involved in the growth of cancer cells and is also involved with other growth factors that cancers use to survive. This trial will test new data that suggests that combining inhibitors may be more effective for colorectal cancer patients. Patients may enroll in this trial once their cancers have progressed after first line treatment to receive standard treatment for second line and if they have the wild-type KRAS tumor marker. Patients will randomly receive irinotecan plus cetuximab and ARQ-197 or irinotecan plus cetuximab and placebo.

To learn if you are eligible for this study, call the CCA’s Clinical Trial Matching Service at (866) 278-0392 to talk to a patient navigator.

Return